Boilerplate clauses

Boilerplate clauses

This subtopic focuses on boilerplate clauses in commercial business-to-business agreements. For information on commercial clauses more generally, see: Commercial clauses—overview.

For information on boilerplate in business-to-consumer contracts, see the section on ‘Consumer boilerplate’ below.

For information on boilerplate in public sector contracts, see the section on ‘Public sector boilerplate’ below.

The role of boilerplate

Lawyers work on a huge variety of transactions, but all of them will in some way involve written agreements. All of those agreements should contain some boilerplate clauses.

‘Boilerplate’ is the term used to describe the clauses that are included in an agreement to deal with the mechanics of how it works and those legal points that are relevant to most transactions. For further consideration of the role and importance of boilerplate clauses, see Practice Note: The role of boilerplate.

Boilerplate clauses are generally found at the beginning and the end of an agreement. Such clauses are often thought of as standard, miscellaneous provisions, but this is a very dangerous view to adopt. It is not unusual for a boilerplate clause to be the cause of litigation. Since a boilerplate clause

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest Life Sciences News

EMA updates parallel distribution FAQ guidance

The European Medicines Agency (EMA) has updated its frequently asked questions (FAQ) guidance document on parallel distribution. The updated version includes changes to several responses concerning parallel distribution procedures, such as: (1) steps to take when an organisation’s details change; (2) what happens if a Notice for Parallel Distribution (PD) cannot be issued; (3) the obligations of parallel distributors following the issuance of a PD notice; (4) the impact of the Protocol on Ireland/Northern Ireland; and (5) clarification on who receives PD notices. In addition to these updates, EMA has added a new FAQ on the requirements for QR codes on packaging material.

Commission adopts implementing regulation on medical device clinical assessments

The European Commission has adopted an implementing regulation establishing rules for joint clinical assessments of medical devices and in vitro diagnostic medical devices under Regulation (EU) 2021/2282 (Health Technology Assessment (HTA) Regulation). The implementing regulation provides detailed procedural rules covering cooperation between the Member State Coordination Group on Health Technology Assessment and the Commission with notified bodies and expert panels, interaction protocols with health technology developers and stakeholders, general procedural rules for stakeholder consultation, and standardised formats for dossiers and assessment reports. This represents the sixth and final implementing regulation required for proper application of the HTA Regulation, which became applicable on 12 January 2025. The regulation will be published in the Official Journal from 20 October 2025, with nine joint clinical assessments currently ongoing for new cancer medicines and advanced therapy medicinal products.

Life Sciences weekly highlights—16 October 2025

This week's edition of Life Sciences weekly highlights includes analysis by Freshfields LLP of recent highlights in the UK's medical devices regulatory framework and an MLex analysis indicating that the European Commission will issue guidelines on how the EU AI Act interacts with other EU laws such as the EU GDPR. Also included is news that MedTech Europe submitted recommendations to the European Commission’s call for evidence on the forthcoming European Innovation Act, the MHRA announced an expanded partnership with the US Food and Drug Administration (FDA) to accelerate innovation in medical technologies and AI and published guidance on new medical device registration fee planned to come into effect on 1 April 2026, and the European Notified Bodies industry group (Team-NB) and the Association of British HealthTech Industries (ABHI) responded to the Commission’s call for evidence on the targeted revision of the MDR and IVDR. Also included, is news that the MHRA has awarded the first three Innovation Passports under its revised Innovative Licensing and Access Pathway (ILAP), and together with NICE have opened early access to the aligned streamlined approvals pathway six months earlier than projected, EU industry bodies have criticised the European Commission’s upcoming study on costs for implementing quaternary-level treatment upgrades under the Urban Wastewater Treatment Directive (UWWTD) and, together with Cosmetics Europe, called for a data-driven, substance-based Extended Producer Responsibility (EPR) scheme, and the European Commission opened a public consultation on its proposed European Research Area Act, among other stories.

MHRA selects seven AI healthcare technologies for AI Airlock programme Phase 2

The Medicines and Healthcare products Regulatory Agency (MHRA) has selected seven AI healthcare technologies for the second phase of its AI Airlock regulatory sandbox programme, scheduled to run until March 2026. These technologies include AI-powered clinical note taking, advanced cancer diagnostics, eye disease detection tools, and obesity treatment support systems. They address three key regulatory challenge areas: the scope of intended use extension and validation, AI-powered in-vitro diagnostic devices, and post-market surveillance with predetermined change control plans.